{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:35:00Z","timestamp":1787841300107,"version":"build-2784847793"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Several clinico-pathological prognostic factors are essential to guide therapeutic management for colon cancer (CC). The benefit of adjuvant chemotherapy remains controversial for patients with stage II CC and is currently not systematically applied. This leads to define two subgroups of patients, \u201clow\u201d and \u201chigh risk\u201d of recurrence. In this setting, tumor-infiltrating lymphocytes (TILs) may represent a promising marker.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>Our study aimed to assess the prognostic value of TILs in stage II CC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>We conducted a retrospective study involving the patients who underwent curative surgery for primary stage II colonic adenocarcinoma. The data were collected over a period of 15 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Seventy patients were included. The mean age of the patients was 60 years. The most frequent circumstances of discovery were abdominal pain (48%), followed by digestive transit disorders (26%) and digestive bleeding (20%). All patients at \u201chigh risk\u201d of recurrence had received adjuvant chemotherapy except for seven patients. The mean overall survival and recurrence-free survival rates were 51 and 56 months, respectively. TILs rate varied between 3% and 80% with a median of 50%. TIL rates &lt; 50% significantly decreased recurrence-free survival in univariate analysis (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001). In multivariate analysis, it was identified as an independent factor for the recurrence-free survival. We found a correlation between the rate of TILs &lt; 50% and the lymphatic invasion (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.022), the high grade of the tumor (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02) and the tumor size &gt;3 cm (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.009).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>TILs represent an important prognostic and predictive factor for stage II CC. It should be introduced in clinical practice to identify patients with \u201chigh-risk\u201d stage II CC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijpm.ijpm_710_24","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T06:00:10Z","timestamp":1774936810000},"page":"10-15","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic value of tumor-infiltrating lymphocytes in colon cancer"],"prefix":"10.4103","volume":"69","author":[{"given":"Bacha","family":"Dhouha","sequence":"first","affiliation":[{"name":"Department of Pathology, University Hospital Mongi Slim, La Marsa, Tunisia"},{"name":"University of Tunis El-Manar, Tunis, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khessairi","family":"Neyssem","sequence":"additional","affiliation":[{"name":"University of Tunis El-Manar, Tunis, Tunisia"},{"name":"Department of Surgical Oncology, Salah Azaiez Institute, Tunis, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kammoun","family":"Neirouz","sequence":"additional","affiliation":[{"name":"University of Tunis El-Manar, Tunis, Tunisia"},{"name":"Department of Visceral Surgery, University Hospital Mongi Slim, La Marsa, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siala","family":"Hager","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital Mongi Slim, La Marsa, Tunisia"},{"name":"University of Tunis El-Manar, Tunis, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lahmar","family":"Ahlem","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital Mongi Slim, La Marsa, Tunisia"},{"name":"University of Tunis El-Manar, Tunis, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gharbi","family":"Lassad","sequence":"additional","affiliation":[{"name":"University of Tunis El-Manar, Tunis, Tunisia"},{"name":"Department of Visceral Surgery, University Hospital Mongi Slim, La Marsa, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben Slama","family":"Sana","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital Mongi Slim, La Marsa, Tunisia"},{"name":"University of Tunis El-Manar, Tunis, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"R1-20260403","first-page":"209","article-title":"Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20260403","first-page":"1","article-title":"Treatment of patients with early-stage colorectal cancer:ASCO resource-stratified guideline","volume":"5","author":"Costas-Chavarri","year":"2019","journal-title":"J Glob Oncol"},{"key":"R3-20260403","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","article-title":"Localised colon cancer:ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Argil\u00e9s","year":"2020","journal-title":"Ann Oncol"},{"key":"R4-20260403","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1093\/annonc\/mds236","article-title":"ESMO consensus guidelines for management of patients with colon and rectal cancer:A personalized approach to clinical decision making","volume":"23","author":"Schmoll","year":"2012","journal-title":"Ann Oncol"},{"key":"R7-20260403","author":"Lakhani","year":"2012","journal-title":"WHO Classification of Tumours of the Breast"},{"key":"R8-20260403","first-page":"93","article-title":"The eighth edition AJCC cancer staging manual:Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201dapproach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R9-20260403","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4132\/jptm.2022.04.25","article-title":"What's new in breast pathology 2022:WHO 5th edition and biomarker updates","volume":"56","author":"Muller","year":"2022","journal-title":"J Pathol Transl Med"},{"key":"R10-20260403","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"R11-20260403","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1002\/1097-0142(19860501)57:9<1866::AID-CNCR2820570928>3.0.CO;2-T","article-title":"Prognostic indicators of colon tumors. The gastrointestinal tumor study group experience","volume":"57","author":"Steinberg","year":"1986","journal-title":"Cancer"},{"key":"R12-20260403","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gtc.2007.12.002","article-title":"Pathophysiology, clinical presentation, and management of colon cancer","volume":"37","author":"Cappell","year":"2008","journal-title":"Gastroenterol Clin North Am"},{"key":"R14-20260403","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.2005.01.086","article-title":"Systematic review of microsatellite instability and colorectal cancer prognosis","volume":"23","author":"Popat","year":"2005","journal-title":"J Clin Oncol"},{"key":"R15-20260403","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1159\/000506706","article-title":"Tissue-infiltrating lymphocytes as a predictive factor for recurrence in patients with curatively resected colon cancer:A propensity score matching analysis","volume":"98","author":"Chan","year":"2020","journal-title":"Oncology"},{"key":"R16-20260403","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.coi.2017.07.004","article-title":"Vaccines targeting helper T cells for cancer immunotherapy","volume":"47","author":"Melssen","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"R17-20260403","doi-asserted-by":"crossref","first-page":"808964","DOI":"10.3389\/fimmu.2021.808964","article-title":"Tumor-infiltrating lymphocytes in colorectal cancer:The fundamental indication and application on immunotherapy","volume":"12","author":"Bai","year":"2022","journal-title":"Front Immunol"},{"key":"R18-20260403","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1038\/bjc.2014.46","article-title":"Tumour-infiltrating inflammation and prognosis in colorectal cancer:Systematic review and meta-analysis","volume":"110","author":"Mei","year":"2014","journal-title":"Br J Cancer"},{"key":"R19-20260403","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1038\/s41598-020-60255-4","article-title":"The prognostic implications of tumor infiltrating lymphocytes in colorectal cancer:A systematic review and meta-analysis","volume":"10","author":"Idos","year":"2020","journal-title":"Sci Rep"},{"key":"R20-20260403","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/archsurg.2012.35","article-title":"Prognostic significance of tumor-infiltrating lymphocytes for patients with colorectal cancer","volume":"147","author":"Huh","year":"2012","journal-title":"Arch Surg"},{"key":"R21-20260403","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1002\/cncr.25293","article-title":"Clinical impact of tumor-infiltrating lymphocytes for survival in stage II colon cancer","volume":"116","author":"Lee","year":"2010","journal-title":"Cancer"}],"container-title":["Indian Journal of Pathology and Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpm.ijpm_710_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:47:26Z","timestamp":1787838446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpm.ijpm_710_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijpm.ijpm_710_24","relation":{},"ISSN":["0377-4929","0974-5130"],"issn-type":[{"value":"0377-4929","type":"print"},{"value":"0974-5130","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2024-08-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}